Zynex, Inc. (NASDAQ:ZYXI) Q4 2022 Earnings Conference Call March 13, 2023 8:30 AM ET Company Participants Louisa Smith - Investor Relations Thomas Sandgaard - Chairman, President and Chief Executive Officer Dan Moorhead - Chief Financial Officer Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Zynex Monitoring Solutions Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Simran Kaur - Piper Sandler Yi Chen - H.C. Wainwright Operator Good morning, ladies and gentlemen and welc ...

Zynex, Inc. (NASDAQ:ZYXI) Q3 2022 Earnings Conference Call October 27, 2022 4:15 AM ET Company Participants Louisa Smith – Investor Relations-Gilmartin Group Thomas Sandgaard – Chairman, President and Chief Executive Officer Dan Moorhead – Chief Financial Officer Anna Lucsok – Chief Operating Officer Donald Gregg – Vice President-Zynex Monitoring Solutions Conference Call Participants Simran Kaur – Piper Sandler Jeffrey Cohen – Ladenburg Thalmann Yi Chen – H.C. Wainwright Marc Wiesenberger – B. Riley Securi ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) | NEVADA | 90-0275169 | | --- | --- | | (State or other jurisdiction of | (IRS Employer | | incorporation or organization) | Identification No.) | | 9655 Maroon Cir. | | | E ...

Zynex, Inc. (NASDAQ:ZYXI) Q2 2022 Results Conference Call July 28, 2022 4:15 PM ET Company Participants Louisa Smith - Investor Relations-Gilmartin Group Thomas Sandgaard - Chairman, President and Chief Executive Officer Dan Moorhead - Chief Financial Officer Anna Lucsok - Chief Operating Officer Don Gregg - Vice President of Zynex Monitoring Solutions Conference Call Participants Simran Kaur - Piper Sandler Jeffrey Cohen - Ladenburg Thalmann Marc Wiesenberger - B. Riley Securities Yi Chen - H.C. Wainwright ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) NEVADA 90-0275169 (State or other jur ...

Table of Contents WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Zynex, Inc. (Exact name of registrant as specified in its charter) NEVADA 90-0275169 (State or other ju ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 ZYNEX, INC. (Exact name of registrant as specified in its charter) Nevada 90-0275169 (State or other jurisdiction of in ...

Zynex, Inc. (NASDAQ:ZYXI) Q4 2021 Earnings Conference Call February 24, 2022 4:15 PM ET Company Participants Thomas Sandgaard – Chairman, President and CEO Dan Moorhead - CFO Anna Lucsok - Chief Operating Officer Donald Gregg - Vice President, Monitoring Division Conference Call Participants Matthew O'Brien - Piper Sandler Yi Chen - H.C. Wainwright Operator Good afternoon, ladies and gentlemen. And welcome to the Zynex Fourth Quarter 2021 Earnings Conference Call. At this time all participants are in listen ...

Financial Data and Key Metrics Changes - The company reported record revenue of $34.8 million for Q3 2021, a 74% increase compared to the same quarter last year and a 12% sequential increase from Q2 2021 [5][17] - Net income increased 118% sequentially from Q2 2021, reaching $6.1 million, which represents a 358% year-over-year increase [5][18] - Gross margins improved to 80% in Q3 2021, up from 77% in Q2 2021, with expectations to maintain margins between 75% and 80% going forward [17][18] Business Line Data and Key Metrics Changes - Device revenue increased 71% year-over-year to $9.1 million, while supplies revenue rose 75% to $25.7 million [17] - Orders grew 70% year-over-year, indicating strong demand across both divisions [17] Market Data and Key Metrics Changes - The company is experiencing a competitive labor market, impacting the hiring of sales representatives, which decreased to approximately 430 by the end of Q3 2021 [6][7] - The average revenue per sales rep increased to approximately $325,000, up $50,000 from Q2 2021 and nearly $100,000 from Q3 2020 [7] Company Strategy and Development Direction - The company aims to grow its share in the prescription pain management market and is considering complementary acquisitions to enhance its product offerings [23][26] - The Monitoring Solutions Division is seeing increased staffing and clinical research activities, with plans to submit the wireless CM-1600 to the FDA by the end of 2021 [9][12] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's growth trajectory, expecting Q4 2021 revenue between $40 million and $43 million, which would represent a 54% to 65% increase compared to Q4 2020 [22] - The company anticipates significant positive cash flow in Q4 due to seasonal factors and continued profitability [22] Other Important Information - The opioid epidemic remains a critical issue, and the company is focused on promoting its non-opioid pain management solutions [8] - The company has no reported supply chain issues and is returning inventory levels to normal [8] Q&A Session Summary Question: Can you discuss the CMS business and potential acquisitions? - The company is exploring opportunities that fit into both the pain management and monitoring solutions divisions, focusing on products with established reimbursement codes [26] Question: What are the expected sales rep numbers by the end of Q4? - The company expects to maintain around 430 sales reps by the end of the year, with minimal net change due to trimming less productive reps [32][33] Question: How do you anticipate the blood monitoring category will impact the business in 2022? - Management is optimistic about the potential revenue from the blood monitoring division, with commercialization plans for the CM-1600 expected in the second half of 2022 [41] Question: What is the current status of the patient monitoring division? - The patient monitoring division has expanded its team significantly, focusing on engineering and clinical trials, with plans for further growth in 2022 [64] Question: How is the company addressing labor constraints? - The company has around 80 to 100 unfilled positions across departments, impacting back-office operations but still managing to process orders effectively [49][50]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-38804 Zynex, Inc. (Exact name of registrant as specified in its charter) NEVADA 90-0275169 (State or othe ...